8-K: Evofem Biosciences Secures Investor Support for Merger with Aditxt Through Voting Agreements

Evofem Biosciences has secured voting agreements from key investors to support its proposed merger with Aditxt, Inc., ensuring a favorable vote at the upcoming Special Meeting of Stockholders.

Summary

• Evofem Biosciences has entered into voting agreements with certain Series E-1 stockholders and convertible noteholders to support the proposed merger with Aditxt, Inc.
• These agreements ensure that these investors will vote in favor of the merger at the upcoming Special Meeting of Stockholders.
• The voting agreements follow a $2.28 million investment by Aditxt in Evofem through the purchase of Series F-1 convertible preferred stock, completing a total of $5 million in investments since May 2024.
• The funds from Aditxt have enabled Evofem to acquire SOLOSEC and to support the uptake of Phexxi among GLP-1 users.
• The merger is contingent upon several closing conditions, including a majority vote from Evofem stockholders and Aditxt raising approximately $17 million, including $15.2 million to satisfy Evofem's senior secured noteholder.
• Failure to secure these funds could result in the senior secured noteholder blocking the merger.
• Evofem plans to file an amended preliminary proxy related to the merger in the near future.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in securing investor support for the merger and the completion of Aditxt's investment. However, the significant funding requirement and the risk of the merger being blocked by the senior secured noteholder temper the optimism.

Positives

• The voting agreements significantly increase the likelihood of the merger being approved by Evofem stockholders.
• The $5 million investment from Aditxt has enabled Evofem to acquire SOLOSEC and support the uptake of Phexxi.
• The merger, if successful, could provide Evofem with additional resources and support from Aditxt's ecosystem.

Negatives

• The merger is contingent on Aditxt raising a substantial $17 million, with a significant portion needed to satisfy Evofem's senior secured noteholder.
• Failure to secure the necessary funding could lead to the senior secured noteholder blocking the merger.
• There is no guarantee that all closing conditions will be met or that the merger will ultimately close.

Risks

• The merger could be terminated if any of the closing conditions are not met.
• There is a risk that Aditxt may not be able to raise the required $17 million to complete the merger.
• The senior secured noteholder could block the merger if their debt is not satisfied.
• The lack of a third-party valuation raises concerns about the fairness of the transaction to Evofem stockholders.
• Legal proceedings could be initiated against the company following the announcement of the merger agreement.

Future Outlook

The company anticipates holding a Special Meeting of Stockholders to vote on the merger and aims to close the transaction shortly thereafter, assuming all closing conditions are met. The company plans to file an amended preliminary proxy related to the merger in the near future.

Management Comments

• Saundra Pelletier, CEO of Evofem, stated that the capital received from Aditxt enabled the acquisition of SOLOSEC and supported initiatives to drive uptake of Phexxi.
• Ms. Pelletier expressed hope for the merger's approval and a close shortly thereafter, assuming closing conditions are met.

Industry Context

This merger is part of a trend of consolidation in the biotech industry, where smaller companies seek to combine resources and expertise to achieve greater scale and market reach. The acquisition of SOLOSEC and the focus on Phexxi uptake among GLP-1 users indicate a strategic move to address specific market needs in women's health.

Comparison to Industry Standards

• The merger between Evofem and Aditxt is similar to other acquisitions in the biotech sector where a larger company acquires a smaller one to expand its product portfolio and market presence.
• The $5 million investment by Aditxt is relatively small compared to larger biotech acquisitions, but it is significant for Evofem's current financial situation.
• The requirement for Aditxt to raise $17 million to close the merger is a common condition in such transactions, reflecting the need for sufficient capital to support the combined entity.
• The voting agreements are a standard practice to ensure shareholder support for the merger, similar to other deals in the industry.

Stakeholder Impact

• Shareholders of Evofem will be impacted by the merger, with the potential for increased value if the merger is successful.
• Employees of Evofem may experience changes in their roles and responsibilities following the merger.
• Customers of Evofem may benefit from the combined company's expanded product offerings.
• Creditors of Evofem, particularly the senior secured noteholder, are impacted by the merger, with the need for their debt to be satisfied for the merger to proceed.

Next Steps

• Evofem will file an amended preliminary proxy related to the merger.
• Evofem will hold a Special Meeting of Stockholders to vote on the merger.
• Aditxt needs to raise approximately $17 million to close the merger.

Key Dates

Keywords

Merger, Voting Agreements, Aditxt, Evofem Biosciences, Stockholders, Convertible Notes, Capital Raise, SOLOSEC, Phexxi, Acquisition